Lexeo Therapeutics (LXEO) Current Assets (2022 - 2026)

Lexeo Therapeutics' Current Assets history runs 5 years deep, the most recent figure standing at $200.9 million for Q1 2026.

• In Q1 2026, Current Assets rose 90.8% year-over-year to $200.9 million; the TTM figure through Mar 2026 stood at $200.9 million (up 90.8% YoY), while the FY2025 annual figure was $188.4 million, up 49.37% from the prior year.
• Current Assets came in at $200.9 million for Q1 2026 at Lexeo Therapeutics, up from $188.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $200.9 million in Q1 2026 to a low of $38.9 million in Q3 2023.
• A 5-year average of $138.9 million and a median of $133.9 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets jumped 310.19% in 2024 and sank 46.86% in 2025, its largest moves.
• Lexeo Therapeutics' Current Assets stood at $80.0 million in 2022, then jumped by 55.27% to $124.3 million in 2023, then climbed by 1.47% to $126.1 million in 2024, then jumped by 49.37% to $188.4 million in 2025, then increased by 6.62% to $200.9 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $200.9 million, $188.4 million, and $127.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison